Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham to conduct Phase IV Nicotrol safety/efficacy study in adolescents.

This article was originally published in The Tan Sheet

Executive Summary

NICOTROL PATCH PHASE IV COMMITMENTS INCLUDE SURVEILLANCE OF SALES TO MINORS and a study of the safety and efficacy of Nicotrol use in adolescents, FDA reminded McNeil in its recent approval letter for the Rx-to-OTC switch nicotine patch therapy. The requirements are nearly identical to those for the other smoking cessation aid recently switched to OTC status -- SmithKline Beecham's Nicorette nicotine replacement chewing gum ("The Tan Sheet" Feb. 19, p. 5).
Advertisement

Related Content

GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned

Topics

Advertisement
UsernamePublicRestriction

Register

PS085597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel